LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.40
From 52W high−88.02%
Volume56338.00
Market cap$4.43M
P/E (TTM)—
P/S (TTM)3.7x
Div yield—
Key dataOct 19, 2026
Open
$1.40
From 52W high
−88.02%
Volume
56338.00
Market cap
$4.43M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
20.7
MomentumView details →
1D Return
+0.00%
YTD Return
−72.13%
SummaryUpdated Jun 1, 2026
Longeveron Inc. (NASDAQ:LGVN) is a clinical-stage biotechnology company founded in 2014 and based in Miami, Florida. The company went public in February 2021 and focuses on developing cellular therapies for aging-related and life-threatening conditions. Longeveron's primary focus is advancing its lead investigational product, LOMECEL-B, a cell-based therapy derived from bone marrow of young healthy adult donors, through various clinical trials targeting rare diseases and age-related conditions.
Similar companies
Latest newsMore news →
Longeveron Inc. reported that Chief Medical Officer Dr. Nataliya Agafonova departed, effective October 14, 2026.5d agoRejuvStem is developing a stem cell manufacturing lab near Miami in partnership with Longeveron Inc..13d agoLongeveron said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.33d ago